Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Liver Fat in T2DM
NCT02686476Completed
- Sponsor
- Medanta
- Start
- Mar 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of empagliflozin in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Medanta. Primary endpoint: Change in liver fat content at 12 weeks. Started Mar 2016; status: completed.
02
Drugs
empagliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02686476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02686476.